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ABSTRACT

MECHANISM GOVERNING THE CELLULAR SUSCEPTIBILITY TO
SECRETORY PHOSPHOLIPASE A2

Lauren B. Jensen
Department of Physiology and Developmental Biology
Master of Science

Secretory phospholipase A2 (sPLA2) is an important part of apoptosis and
disposal of damaged and dying cells. However, healthy cells are not susceptible to attack
by sPLA2. Recent studies have focused on membrane properties necessary to induce
susceptibility in both artificial and biological membranes. Hydrolysis of phospholipids
by sPLA2 requires at least two preliminary steps: first, adsorption of the enzyme to the
cellular membrane, and second, movement of a phospholipid into the active site of the
enzyme. We determined the effects of susceptibility on each of the two steps and
determined the contributions changing the equilibrium constants have on susceptibility.
The equilibrium constant for step one increased by a factor of 2 during susceptibility,
while the equilibrium constant for step two increased by a factor of 4. The rise in the
second equilibrium constant caused the majority of the change in hydrolysis rate seen
during susceptibility; the influence of the first equilibrium constant is minimal. We

confirmed these results with adsorption studies (assessment of the first step). We
additionally found that sPLA2 has a high affinity for the cellular membrane and that only
a small percentage (3-5%) of the membrane is covered when all adsorption sites are filled
by the enzyme. We proposed a mathematical model describing the mechanism of action
of sPLA2, and we were able to experimentally justify the assumptions made in the model.
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INTRODUCTION
Secretory phospholipase A2 (sPLA2) is a low-molecular weight, extracellular
protein involved in the inflammation process and cellular apoptosis (1-8). It has also
been implicated in the pathology of septic shock (9). During cellular trauma, sPLA2
adsorbs to the cellular membrane and hydrolyzes phospholipids at the sn-2 position,
creating fatty acids and lysophospholipids. The byproducts of phospholipid hydrolysis
are further converted to inflammation factors (leukotrienes, arachidonic acid, etc.).
Healthy cells resist attack by sPLA2, but damaged or dying cells are susceptible to
hydrolysis (6-11). In this manner sPLA2 is able to dispose of phospholipids of damaged
and dying cells, but healthy cells are not affected.
Initial studies using artificial vesicles have shown that the enzyme is able to
adsorb to membranes and hydrolyze the phospholipids (12,13). Additional experiments
have described the properties that make artificial membranes susceptible to attack by
sPLA2: the lipid composition of the membrane and the concentration of hydrolysis
products, temperature, vesicle curvature (14-18). However, these experiments do not
necessarily represent enzyme-membrane interactions in biological systems. Erythrocytes
are a simple model for studying biological membrane susceptibility to sPLA2 as they
resist attack by sPLA2 when healthy but changes in the membrane lead to susceptibility
(11,19).
Calcium has a dual role during membrane attack by sPLA2. Extracellular calcium
serves as a cofactor for the enzyme and is necessary for hydrolysis to occur (20).
Intracellular calcium affects the properties of the membrane, influencing susceptibility to
the enzyme (21). We will be exploiting this duality to control susceptibility and isolate
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certain steps in the hydrolysis process. Barium interferes with the calcium as a cofactor
(22), but still allows intracellular calcium to change the membrane properties essential for
susceptibility. Ionomycin is a calcium ionophore that increases intracellular calcium,
which we will use to influence the membrane properties to increase susceptibility (11).
Ionomycin does not affect the function of extracellular calcium as an enzyme cofactor.
The events leading to hydrolysis of phospholipids by sPLA2 can be described by a
two-step model (shown in Scheme 1): first, adsorption of the enzyme to the cellular
membrane; and second, movement of a phospholipid into the active site. Changes in
either or both steps may lead to increased susceptibility. Our ultimate goal is to produce
a mathematical model describing the mechanism of action of sPLA2 and how
susceptibility affects the action of the enzyme. Unpublished data from our lab showed
that changing the temperature affects susceptibility through both steps in the two-step
model. Additional unpublished data from our lab showed that increasing intracellular
calcium concentration increases the tendency of a phospholipid to move out of the
membrane and into the active site of the enzyme (the second step).
We studied the influence of increasing susceptibility on each step of the model by
changing intracellular calcium concentration (by treating the cells with ionomycin). We
found that the second step was greatly increased during susceptibility, while step one was
only slightly changed. We were able to validate the results for step one: the effect of
ionomycin treatment on adsorption individually was not significantly different than
control. Additionally, we justified experimentally the assumptions made in our
mathematical model. Finally, we quantified the number of sPLA2 adsorption sites on the
cell surface.
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MATERIALS AND METHODS
Materials
Erythrocytes were obtained from healthy individuals receiving blood tests during
physical examinations at the Brigham Young University Student Health Center. The
samples were stored overnight at 4 ºC in EDTA vacutainers from which patient
identification was removed. The storage conditions did not influence the results (11).
Erythrocytes were isolated by centrifugation, and resuspended to the original hematocrit
in modified balanced salt solution (MBSS; 134 mM NaCl, 6.2 mM KCl, 1.6 mM CaCl2,
1.2 mM MgCl2, 18 mM HEPES, 13.6 mM glucose, pH 7.4 at 37 ºC), high-barium, lowcalcium, low-magnesium medium (LCBM; 134 mM NaCl, 6.2 mM KCl, 1.6 mM BaCl2,
18 mM HEPES, 13.6 mM glucose, pH 7.4 at 37 ºC) or high-barium medium (BMBSS;
134 mM NaCl, 6.2 mM KCl, 6.4 mM BaCl2, 1.6 mM CaCl2, 1.2 mM MgCl2, 18 mM
HEPES, 13.6 mM glucose, pH 7.4 at 37 ºC).
Secretory PLA2 was isolated from the venom of Agkistrodon piscivorus
piscivorus according to published procedure (23). This form of sPLA2 represents a
reliable model for the human forms of the enzyme (9,11). Stock solutions of the enzyme
(1.15 mg/ml, 1.0 mg/ml, 0.77 mg/ml, and 0.1 mg/ml) were prepared in 50 mM KCl with
3 mM NaN3 and stored at 4 ºC.
Acrylodan-labeled fatty acid-binding protein (ADIFAB) was obtained from
Molecular Probes (Eugene, OR). Ionomycin was purchased from Calbiochem (La Jolla,
CA) and dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 120 µM.
Fluorescamine was purchased from Sigma (St. Louis, MO) and dissolved in acetone at a
stock solution of 3.0 mg/ml.
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Methods
Membrane hydrolysis by sPLA2 – Release of free fatty acids from erythrocytes
was assayed with ADIFAB (65 nM final concentration, excitation: 390 nm, emission: 432
nm and 505 nm). Washed erythrocytes were suspended in 2 ml MBSS in a fluorometer
sample cell to a final density of approximately 1-2×106 erythrocytes per ml and
equilibrated at 37 ºC. Fluorescence data were acquired on a photon-counting
spectrofluorometer (Fluoromax (Jobin Yvon Horiba, Edison, NJ, USA)). After initiating
data acquisition, ADIFAB was added at 30 s, followed by ionomycin (300 nM) or DMSO
at 130 s, and sPLA2 (21 nM-700 nM) at 730 s. Hydrolysis results were quantified by
calculation of generalized polarization (GP) and fit as described (11) using statistical
software (Prism 3.0 or Prism 4.0). The initial hydrolysis rate was approximated as the
amount of reaction product generated at 20 s following sPLA2 (using coefficient values
from the nonlinear regression results).
Fluorescamine labeling – Fluorescamine (180 µM final concentration, excitation:
390 nm, emission: 485 nm) was added to sPLA2 (1.4 µM) and allowed to react at 37 ºC.
Progression of the labeling reaction was monitored by fluorescence spectroscopy as
described above.
Two-photon microscopy – Scanning two-photon excitation microscopy images
were collected on an Axiovert 35 inverted microscope (Zeiss, Thornwood, NY, USA) at
the Laboratory for Fluorescence Dynamics (Urbana, IL) as described previously (24).
The excitation source was a titanium-sapphire laser (Coherent, Palo Alto, CA, USA)
tuned to 780 nm and pumped by a frequency-doubled Nd:vandate laser. Power was set at
80-100 mW. Secretory PLA2 was labeled with fluorescamine as described above.
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Washed erythrocytes were mixed with 1 ml BMBSS in a temperature-controlled
microscopy dish (approximately 1-2×106 erythrocytes per ml) and allowed to equilibrate
at 37 ºC. Ionomycin (300 nM) or DMSO was added, and the mixture was incubated at
least 5 min. To quantify adsorption, images were acquired at multiple time points before
and after addition of fluorescamine-labeled sPLA2. Total fluorescence intensity (after
subtraction of a background threshold) was measured for each image. Slopes of the
fluorescence trends were calculated by linear regression using image number as the
independent variable and intensity as the dependent variable. The difference between the
slopes of increasing fluorescence before and after addition of labeled enzyme were
calculated and compared as a function of enzyme concentration.
Adsorption site quantification – Secretory PLA2 was labeled with fluorescamine
as described above. Washed erythrocytes were suspended in 1 ml LCBM in a
microcentrifuge tube to a final density of approximately 1-2×106 erythrocytes per ml.
Fluorescamine-labeled sPLA2 (70 nM) was added, and the mixture was incubated at least
10 min at 37 º C. The mixture was centrifuged (G force: 15,000 g units) for 15 s, and the
pellet was washed and resuspended in 2 ml LCBM. Fluorescence data were acquired on
a Fluoromax. Control experiments were performed without erythrocytes or without
fluorescamine-labeled sPLA2 to measure noise.
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DESCRIPTION OF MODEL
The model describing the action of sPLA2 on the surface of membranes is shown
in Scheme 1. The rate of hydrolysis (dP/dt) is given by the following:

dP
= k cat E BS
dt

(1)

Experiments were conducted in which the concentration of cells and, therefore, the total
number of binding sites for the enzyme (MST) were kept constant. The equilibrium
constants (K1 and K2) are defined as follows:
EB
( E )( M S )

(2)

E BS
K2 =
( E B )( S )

(3)

K1 =

If we confine our analysis to the initial part of the hydrolysis time course, then S can be
assumed to be a constant mole fraction of MST (S0). Since S0 is a constant, the apparent
value of K2 (K2*) is proportional to K2 and can be used in our calculations:

E BS
K =
EB
*
2

(4)

The distribution of membrane binding sites between occupied and unoccupied states is
given by:

M ST = M S + E B + E BS

(5)

If we assume that only a small fraction of added enzyme adsorbs to the cell surface, then

E can be approximated by the total enzyme concentration, ET. This assumption was
verified by binding experiments described in the next section. An explicit description of
the initial hydrolysis rate can be obtained by combining equations 1, 2, and 4:
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αET K 1 K 2*
dP
=
dt 1 + ET K 1 + ET K 1 K 2*
where α is proportional to k cat M ST .
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(6)

RESULTS AND DISCUSSION
We assumed that changing membrane properties that lead to susceptibility to
attack by sPLA2 affects either or both of the two steps prior to hydrolysis described in
Scheme 1. The initial hydrolysis rate of cellular membranes can be used to find the
change in equilibrium constants during susceptibility. Assessment of adsorption (step
one) can validate the hydrolysis kinetics results. Quantification of the number of
adsorption sites can justify the assumptions made in the model, along with giving us
more details about the mechanism of action of sPLA2.

Hydrolysis kinetics
The fluorescent fatty acid-binding protein, ADIFAB, is a useful probe for
studying hydrolysis, since the shape of its emission spectrum changes upon binding to
free fatty acids (products of phospholipid hydrolysis). ADIFAB is excited at 390 nm and
emits with a peak at 432 nm when free in solution. However, the emission curve shifts to
505 nm when ADIFAB is bound to fatty acids. Generalized polarization (GP) is a
comparison between the emission curves of bound and unbound ADIFAB and is
determined using equation 7.

GP =

b−a
b+a

(7)

where a is the emission intensity at 432 nm and b is the intensity at 505 nm. An increase
in GP indicates a shift toward 505 nm and, therefore, an increase in hydrolysis of
phospholipids. The time courses of hydrolysis were fit to equation 8 using nonlinear
regression.

y = A(1 − e − Bt ) + C (1 − e − Dt ) + Et + F
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(8)

where y is the amount of hydrolysis at time t. Figure 1 shows a time course of hydrolysis
of phospholipids using this probe at 21 nM (black squares) and 700 nM (red triangles)
sPLA2. As can be seen, sPLA2 causes hydrolysis of phospholipids within the range of
concentrations examined.
The model assumes that the total number of binding sites and total initial substrate
concentration remain the same at all experimental conditions. However, the data in
Figure 1 seem to violate this assumption. The time courses reached a “plateau” phase
within 200 s that appear to become parallel, suggesting that the total amount of substrate
available for hydrolysis varies with enzyme concentration. To explore this possibility,
we repeated the experiments of Figure 1 for much longer periods of time (Figure 2).
These long-term experiments showed that the “plateau” phase of hydrolysis seen at the
end of the time courses in Figure 1 actually represented slow hydrolysis that continued
for multiple hours. Consequently, at true completion of the reaction, the time courses
did, in fact, converge at 70 nM (black) and 700 nM (red). Thus, these experiments
validated the model’s assumption that the total amount of substrate available for
hydrolysis per cell is constant.
Ionomycin treatment changed the shape of the hydrolysis time course. Cells were
treated with the ionophore 10 min prior to addition of 21 nM (black squares) or 700 nM
(red triangles) sPLA2 (Figure 3). The amount of hydrolysis was determined by ADIFAB.
Hydrolysis increased rapidly initially and required much less time to approach a true
plateau at which the hydrolysis curves at both high and low concentrations of enzyme
converged.
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Initial hydrolysis rate changed as a function of the concentration of sPLA2 (Figure
1, Figure 3). Cells were treated with or without ionomycin before addition of various
concentrations (21 nM, 70 nM, 210 nM, or 700 nM) of sPLA2. Hydrolysis was measured
with ADIFAB and hydrolysis curves fit to equation 8. The values of the coefficients
were used to determine the rate of hydrolysis at 20 s. Twenty seconds was determined to
be the earliest time at which hydrolysis measurements are reliable. Accordingly, this
time point was defined as “initial hydrolysis” and used for comparison among various
concentrations. Figure 4 shows the results of this comparison—red triangles: initial
hydrolysis rates of ionomycin-treated cells; black squares: initial hydrolysis rates of
control (untreated) cells. The hydrolysis rate of cellular membranes increased
significantly with ionomycin treatment at all sPLA2 concentrations: a two-way analysis
of variance showed that treatment with ionomycin accounted for 34.3% of the total
variation (p<0.0001) and increasing the enzyme concentration accounted for 14.1% of the
total variation (p=0.0079). The interaction between the two terms was not significant.
The relationship between hydrolysis rate and the equilibrium constants was
mathematically defined in Description of Model and can be used to determine the change
in the equilibrium constants upon an increase in susceptibility for both steps in our
model. Global analysis was performed on the data collected for Figure 4 using equation
6. As stated earlier, α is a constant that represents kcat, or hydrolysis of the phospholipid
once it has moved into the active site. We assumed that α was not dependent upon the
level of membrane susceptibility because we assumed that once the phospholipid has
moved out of the membrane and into the active site of the enzyme, it is no longer affected
by the membrane properties that determine susceptibility. We, therefore, constrained α to
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remain equal between the two conditions (ionomycin-treated cells and control cells).
Table 1 and Figure 5A show the results of the global analysis (red triangles: ionomycintreated cells; black squares: control cells). Changing the membrane properties by
increasing intracellular calcium amplified the equilibrium constant for the first step (K1)
by a factor of two and the equilibrium constant for the second step (K2*) by a factor of
four. In other words, the affinity of sPLA2 for the cellular membrane doubled and the
probability of a phospholipid moving into the active site of the enzyme quadrupled.
Figure 5B shows the effects of this increase in the individual steps. The solid black line
(and black squares) indicates the initial hydrolysis rate of control cells; the solid red line
(and red triangles) indicates the initial hydrolysis rate of ionomycin-treated cells.
Increasing only K1 by the factor of two is indicated by the dotted line. The dotted line
very closely resembles the solid black line and is within the error bars of the black
squares. Increasing only K2* by the factor of four is indicated by a dashed line. The
dashed line very closely resembles the solid red line and is within the error bars of the red
triangles. Thus, the increase in K2* contributes the majority of the effect of susceptibility,
while the increase in K1 merely refines the curve.

Step 1: Adsorption kinetics
In order to study the adsorption of sPLA2 to the cellular membrane, we labeled
the enzyme with fluorescamine, a fluorescent probe that covalently binds to primary
amines (25). Fluorescamine is fluorescent only when attached to amines; the
fluorescence of residual probe is destroyed by reaction of free fluorescamine with water.
Fluorescamine is excited at 390 nm and emits at 485 nm. Because labeling of sPLA2
requires covalent modification, we conducted experiments to determine if this covalent
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modification changed the behavior of the enzyme. Various concentrations of
fluorescamine-labeled sPLA2 (17 nM, 35 nM, and 70 nM) were added to ionomycintreated or control erythrocytes. Hydrolysis was measured with ADIFAB and hydrolysis
curves fit to equation 8. Unfortunately, ADIFAB and fluorescamine are excited and emit
at the nearly identical wavelengths, changing the overall emission curve and affecting
ADIFAB GP. Additionally, sPLA2 binds to the walls of the cuvette over time, decreasing
the amount of fluorescamine fluorescence. These issues complicated interpretation of the
results. Figure 6A shows the results of a hydrolysis time course at 70 nM sPLA2 (red:
ionomycin-treated cells; black: control cells). Hydrolysis did occur and was greater in
susceptible (ionomycin-treated) cells than in control cells. This result was made more
apparent by considering the difference between the data from control and ionomycintreated samples at 17 nM (black), 35 nM (blue), and 70 nM (red) sPLA2 (Figure 6B). As
in Figure 4, ionomycin-treated cells were initially hydrolyzed at a faster rate than control
cells (seen by a positive difference) at all enzyme concentrations. Additionally,
hydrolysis by fluorescamine-labeled sPLA2 increased with increasing enzyme
concentration (Figure 6B), similar to the results seen in Figure 3. Hence, covalent
labeling of sPLA2 with fluorescamine did not change the enzyme’s general behavior
toward cell membranes.
To determine the nature of adsorption of the enzyme to a cellular membrane, we
observed fluorescence before and after adding fluorescamine-labeled sPLA2 (Figure 7).
Panel A is a field of untreated cells; Panel B is the same field of cells after adding 35 nM
fluorescamine-labeled sPLA2; Panel C is the same field 6 min after adding 2.9 µM
unlabeled sPLA2. The amount of fluorescence did not decrease after adding unlabeled
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enzyme, indicating that desorption of sPLA2 from the cellular membrane was very slow
or that the enzyme bound nonspecifically. To determine the specificity of binding, we
reversed the order of addition: 700 nM unlabeled sPLA2 21 min before 70 nM
fluorescamine-labeled sPLA2. Panel D shows the results of this order of addition: the
fluorescamine-labeled sPLA2 was not able to compete for the adsorption sites already
filled by unlabeled enzyme. Thus, adsorption of sPLA2 to the cellular membrane
appeared to be specific and long-lived.
The influence of increasing membrane susceptibility on adsorption of the enzyme
to the cell surface was also viewed through two-photon microscopy. We treated cells
with or without ionomycin and acquired multiple images of the same field before and
after addition of 14 nM or 70 nM fluorescamine-labeled sPLA2. Total intensity was
calculated for each image and plotted as a function of total number of scans. The slope
for increasing fluorescence was determined through linear regression. The fluorescence
slope before addition of labeled enzyme constituted an increase in autofluorescence from
the power of the microscope. The fluorescence slope after addition of labeled enzyme, if
higher than the fluorescence slope before addition of labeled enzyme, signified
adsorption of labeled enzyme to the cellular membrane. We determined the normalized
difference between the fluorescence slopes before and after addition of labeled enzyme
(see equation 9).
SB − SA
SB

(9)

where SB represents the fluorescence slope before addition of labeled enzyme and SA
represents the fluorescence slope after addition of labeled enzyme. The normalized
difference was plotted as a function of increasing enzyme concentration (Figure 8—red
13

triangles: ionomycin-treated cells; black squares: control cells). The amount of
adsorption did not significantly increase in susceptible cells compared to control cells.
Two-way analysis of variance revealed that the effect of enzyme concentration explained
48.8% of the variation seen (p=0.013), while the effects of ionomycin could rationalize
only 1.2% of the variation (p=0.57). Thus, the increase in fluorescence was accounted
for by the amount of enzyme added; ionomycin did not significantly increase the
adsorption of sPLA2 to the cellular membrane. The interaction between two terms was
almost significant (p=0.2); a larger sample size may lead to a significant interaction term.
These data justify our conclusion from the global analysis of hydrolysis kinetics that a
change in K1 does not significantly contribute to susceptibility.

Quantification of the number of sPLA2 adsorption sites on the cell surface
Similar experiments were used to quantify the number of sPLA2 binding sites on
the cellular membrane. We incubated cells in a “calcium-free” (barium replaced
calcium) buffer with 70 nM fluorescamine-labeled sPLA2. We centrifuged the
suspension and measured the fluorescence of the washed pellet. Control experiments
were conducted without erythrocytes or without labeled enzyme to measure background
noise. The amount of fluorescence in the washed pellet is proportional to the amount of
labeled enzyme adsorbed to the cellular membrane. The potential number of binding
sites was determined by comparing the total surface area of the enzyme to the total
surface area of an erythrocyte and assuming that the surface of the erythrocyte was
covered by enzyme (26,27). Table 2 compares the measured number of binding sites to
the potential number of binding sites. Our measurements suggested that only 2-4% of the
erythrocyte membrane is covered by sPLA2.
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Our results estimated that 2.68×105 enzymes are adsorbed to each cell. We added
approximately 4.0×106 cells per 2 ml cuvette, totaling 1.072×1012 enzymes adsorbed per
2 ml cuvette. When we added 700 nM sPLA2 to the 2 ml cuvette, we added
approximately 8.43×1014 enzyme molecules per 2 ml cuvette. Thus, 0.172% of the
enzyme added was adsorbed to the cells. Even if the cell were completely covered with
sPLA2, 3.4×1013 enzymes, or 4.03% of the total enzyme added, would be adsorbed per
sample. Thus, our assumption that E can be approximated by ET is justified.
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FINAL COMMENTS
Our ultimate goal is to define a mathematical model that describes the mechanism
of action of sPLA2 and explains susceptibility within that mechanism of action. These
results suggest that our two-step model applies to biological systems. We were able to
validate the assumption that MST remains constant and that E can be approximated by ET.
Additionally, we were able to resolve the contributions of each step (K1 and K2*) on the
level of cellular susceptibility using our model. This study argues that the model is
sufficient to explain the mechanism of action of sPLA2 toward both resistant and
susceptible membranes.
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Table 1: Global analysis of effect of ionomycin on initial hydrolysis rate.
Values of K1, K2, and α for susceptible and control erythrocytes obtained during the
global analysis for Figure 5.
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Table 2. Quantification of the number of adsorption sites for sPLA2 on erythrocyte
membranes. Theoretical binding sites assume complete coating of the cell by enzyme as
calculated by the ratio of the surface area of the cell to the surface area of sPLA2. The
measured number of sites was obtained by quantifying the amount of fluorescaminelabeled sPLA2 retained following centrifugation and washing of cells labeled as shown in
Figure 7.
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FIGURE LEGENDS
Scheme 1: Description of the two-step model. Secretory PLA2 requires at least
two steps prior to hydrolysis: first, free enzyme (E) adsorbs to adsorption sites on the
membrane (MS) to become bound enzyme (EB); and second, a phospholipid (S) moves
from the membrane into the active site of the enzyme (EBS). Ultimately, hydrolysis of the
phospholipid occurs, creating free fatty acid and lysophospholipid (P). The enzyme
remains bound. Equilibrium constants for the two steps are given as K1 and K2 and the
hydrolysis rate constant is given by kcat.
Figure 1: Effect of enzyme concentration on the early time courses of
erythrocyte hydrolysis by sPLA2. Control erythrocytes were incubated with 21 nM
(black squares) or 700 nM (red triangles) sPLA2 for 300 s, and hydrolysis was assayed by
ADIFAB fluorescence as described in Materials and Methods. Hydrolysis was
quantified as GP and curves were obtained with nonlinear regression (as described in the
text). Each datum represents the mean ± S.E. of data from seven blood samples.
Figure 2: Extended time courses of erythrocyte hydrolysis at high and low
concentrations of sPLA2. Control erythrocytes were incubated with 70 nM (black) or
700 nM (red) sPLA2 for 1 to 3 h and hydrolysis assayed as described for Figure 1.
Figure 3: Effect of ionomycin treatment on time courses of erythrocyte
hydrolysis at high and low concentrations of sPLA2. The experiments of Figure 1
were repeated using ionomycin-treated erythrocytes (see Materials and Method). Each
datum represents the mean ± S.E. of data from seven blood samples.
Figure 4: Effect of ionomycin treatment on the enzyme-concentration
dependence of the initial rate of hydrolysis of erythrocytes. Various concentrations
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(21 nM, 70 nM, 210 nM, and 700 nM) sPLA2 were added to ionomycin-treated (red
triangles) or control erythrocytes (black squares) and hydrolysis assessed as in Figure 1.
The initial rates of hydrolysis were ascertained from time courses such as those shown in
Figures 1 and 3 and analyzed as explained in Materials and Methods. Each datum
represents the mean ± S.E. of data from seven blood samples.
Figure 5: Global Analysis of effect of ionomycin on initial hydrolysis rate.
The data obtained for Figure 4 were analyzed with global analysis (as described in the
text) based on the relationship between hydrolysis rate and equilibrium constants
(mathematically defined in Description of the Model). Panel A: Hydrolysis curves
obtained by global analysis with α held constant (red: ionomycin-treated erythrocytes;
black: control erythrocytes). Panel B: The contributions to susceptibility of increasing
each equilibrium constant separately (red: ionomycin-treated erythrocytes; solid black:
control erythrocytes; dotted black: increasing K1 by a factor of 2; dashed black:
increasing K2 by a factor of 4).
Figure 6: Control for possible effects of fluorescamine labeling on behavior
of sPLA2. Fluorescamine-labeled sPLA2 was added to ionomycin-treated or control
erythrocytes and hydrolysis was assayed as described in Figure 1. Panel A: Sample time
course of hydrolysis (red: ionomycin-treated erythrocytes; black: control erythrocytes).

Panel B: Differences between hydrolysis of ionomycin-treated erythrocytes and
hydrolysis of control erythrocytes at 18 nM (black), 35 nM (blue), and 70 nM (red)
sPLA2.
Figure 7: Visualization of adsorption of fluorescamine-labeled sPLA2 to
erythrocyte membranes with two-photon microscopy. Panel A: baseline fluorescence
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prior to addition of labeled sPLA2. Panel B: same sample following addition of 35 nM
fluorescamine-labeled sPLA2. Panel C: same sample as B 6 min following addition of
2.9 µM unlabeled sPLA2. Panel D: new sample with 700 nM unlabeled sPLA2 added 21
min prior to 70 nM labeled sPLA2. Experiments were conducted in buffer containing
barium to inhibit extraction and hydrolysis of membrane phospholipids using the twophoton procedure described in Materials and Methods.
Figure 8: Effect of ionomycin treatment on adsorption of sPLA2 to
erythrocyte membranes. Various concentrations (0, 14 nM, or 70 nM) of
fluorescamine-labeled sPLA2 were added to ionomycin-treated or control erythrocytes
and images acquired as in Figure 7. The amount of fluorescence attributed to adsorption
of labeled sPLA2 was quantified as described in Materials and Methods. Two-way
analysis of variance revealed that the effect of enzyme concentration was significant (p =
0.013), but the effects of ionomycin were not (p = 0.57). Each datum represents the mean
± S.E., n = 1 to 4 blood samples.
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